DAWNZERA Trademark

Trademark Overview


On Monday, June 5, 2023, a trademark application was filed for DAWNZERA with the United States Patent and Trademark Office. The USPTO has given the DAWNZERA trademark a serial number of 98027561. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, March 12, 2024. This trademark is owned by Ionis Pharmaceuticals, Inc.. The DAWNZERA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; providing medical and scientific research and medical and scientific research information in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; compiling data for research purposes in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders
dawnzera

General Information


Serial Number98027561
Word MarkDAWNZERA
Filing DateMonday, June 5, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, March 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 22, 2023

Trademark Statements


Goods and ServicesPharmaceutical research and development in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; providing medical and scientific research and medical and scientific research information in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; compiling data for research purposes in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, July 9, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIonis Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCarlsbad, CA 92010

Party NameIonis Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCarlsbad, CA 92010

Trademark Events


Event DateEvent Description
Sunday, July 9, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 8, 2023NEW APPLICATION ENTERED
Tuesday, July 18, 2023ASSIGNED TO EXAMINER
Tuesday, July 18, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 2, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 22, 2023PUBLISHED FOR OPPOSITION
Tuesday, August 22, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 17, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 12, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, March 12, 2024SOU EXTENSION 1 FILED
Tuesday, March 12, 2024SOU EXTENSION 1 GRANTED
Wednesday, March 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED